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Abstract
The Ki-67 labeling index has been reported to discriminate luminal A (LA)-like and luminal B-like subtypes in
patients with hormone-receptor positive, HER2-negative breast cancer. We analyzed prognostic factors
including progesterone receptor (PR) expression. PR expression and tumor size were independent prognostic
factors in the LA-like subtype, and the LA/PR-negative subtype had the higher risk of recurrence, especially
late recurrence.
Introduction: We showed the clinical implications of the Ki-67 labeling index (LI) in hormone receptor (HR)-positive,
HER2-negative (HER2) breast cancer patients with lower risk (luminal A [LA]-like) and higher risk (luminal B [LB]-like)
subtypes. Patients and Methods: Three hundred sixty-nine patients with HRþ, HER2 cancers were eligible and we
dichotomized these patients into LA-like and LB-like according to Ki-67 LI (14% cutoff) and analyzed prognostic
signiﬁcance of progesterone receptor (PR) expression. Results: Of 205 LA-like and 163 LB-like subtypes, PR was
positive in 149 (73%) and 103 (63%). PR expression was a prognostic factor in the LA-like subtype but not in the LB-
like subtype. In LA/PRþ, LA/PR, and LB-like subtypes, the 12-year disease-free survival (DFS) rates were 94.8%,
81.6%, and 79.7% (P ¼ .03), and breast cancer-speciﬁc survival (BCSS) rates were 98.4%, 97.4%, and 92.0%,
respectively (P ¼ .05). Late recurrence occurred in LA/PR subtype, and differences in prognosis between LA/PRþ and
LA/PR subtypes emerged >5 years after surgery. Twelve-year DFS rates of the LA/PR subtype were almost equal to
those of the LB-like subtype, whereas 12-year BCSS of the LA/PR subtype was superior to that of the LB-like
subtype. In multivariate analysis, PR expression and tumor size were signiﬁcant or nearly signiﬁcant prognostic
factors. Conclusion: PR expression and tumor size were independent prognostic factors in the LA-like subtype, and
the LA/PR subtype had the higher risk of recurrence, especially late recurrence, than the LA/PRþ subtype. In LA-like
breast cancers, stratiﬁcation of prognosis according to PR expression and tumor size is important.
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Breast cancer is the most common cancer in women. The mor-
tality in Western countries is decreasing because of early detection
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diagnosed in 2010, with more than 12,000 deaths in 2012.1 More
than half of newly diagnosed Japanese breast cancer patients are
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Table 1 Clinicopathological Features of 368 Patients With
Luminal/HER2L Node-Negative Invasive Breast
Cancers (n [ 368)
Characteristic Patient n (%)
Age, Years
50 145 (40)
>50 223 (60)
Menopause
Premenopausal 151 (41)
Postmenopausal 217 (59)
Invasive Tumor Size, cm
2.0 275 (75)
>2.0 to 5.0 89 (24)
>5.0 4 (1)
Histology
IDC 302 (82)
Mucinous carcinoma 25 (7)
Invasive lobular carcinoma 22 (6)
IDC with predominantly intraductal component 17 (4)
Other (medullary, tubular) 2 (1)
Ki-67 (‡10%)
Positive 221 (60)
Negative 147 (40)
Ki-67 (‡14%)
Positive 163 (44)
Negative 205 (56)
Ki-67 (‡20%)
Positive 87 (24)
Negative 281 (76)
Histological Grade
1 103 (28)
2 175 (47)
3 88 (24)
Unknown 2 (1)
Nuclear Grade
1 155 (42)
2 103 (28)
3 109 (30)
Unknown 1 (0)
Lymphovascular Invasion
Positive 138 (37)
Negative 230 (62)
Adjuvant Chemotherapy
Yes 152 (41)
CMF 100 (65)a
UFT 52 (34)a
CEF 1 (1)
No 216 (59)
Hormone Therapy (Tamoxifen)
Yes 187 (51)
No 181 (49)
Abbreviations: CEF ¼ cyclophosphamide, epirubicin, and 5-ﬂuorouracil; CMF ¼ cyclophospha-
mide, methotrexate, and 5-ﬂuorouracil; IDC¼ invasive ductal carcinoma; UFT¼ oral tegafur-uracil.
a
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PR in Node-Negative Luminal A-Like Breast Canceror distant recurrence within 10 years of the diagnosis in 10% to
15% of these patients.2,3 Therefore, it has been important to
establish criteria for identifying the high-risk patient groups for
whom adjuvant chemotherapy might be beneﬁcial.
Breast cancer has been reported to be a heterogeneous disease in
previous studies in which a molecular subtype classiﬁcation of
invasive breast cancers using gene expression analysis was correlated
with chemotherapeutic response and clinical outcome.4 In clinical
practice, simpliﬁed intrinsic subtype classiﬁcation using immuno-
histochemistry (IHC) is widely used for treatment choice in the
neoadjuvant or adjuvant settings.5-7 Hormone receptor (HR)-
positive breast cancers are in practice classiﬁed into luminal A (LA)-
like subtype and luminal B (LB)-like subtype with or without
HER2 overexpression. The LA-like subtype is shown to express
high levels of HR and a favorable prognosis. In contrast, the LB-like
subtype presents with a worse prognosis compared with the LA-like
subtype.8 In discriminating between LA-like and LB-like subtypes
without HER2 overexpression, Ki-67 labeling index (LI) has been
shown to be useful.7 We previously reported that Ki-67 LI was
useful as a prognosticator to identify high-risk node-negative
luminal/HER2-negative (HER2) tumors in Japanese patients
regardless of 3 different cutoff values.9 In these cases, it was shown
that any of the Ki-67 LI cutoff values (10%, 14%, and 20%), could
be applicable in making determinations between high-risk and low-
risk luminal/HER2 node-negative invasive breast cancers.
A recent study showed that progesterone receptor (PR) expression
as well as Ki-67 LI using IHC were important prognostic factors in
luminal/HER2 breast cancer, which suggests the utility of PR as a
marker for differentiation between LA-like and LB-like subtypes.6
Actually, previous reports revealed that PR expression was a prog-
nostic factor in HRþ breast cancer.10 In this study, we evaluated the
prognostic signiﬁcance of PR expression using the cohort in whom
Ki-67 LI was previously examined9 and investigated optimal cutoff
levels of Ki-67 LI and PR expression.
Patients and Methods
Patient Selection and Data Collection
Details of patient selection were shown in our previous study.9
Brieﬂy, of 530 consecutive patients with pathologically node-
negative invasive primary breast cancer, 369 (70%) with HR-
positive and HER2 (luminal/HER2) tumors were identiﬁed.
We reviewed the medical charts and extracted patient data including
age, regimens of adjuvant chemotherapy and endocrine therapies,
and dates of recurrence, death, or the last follow-up examination.
Methods for formalin-ﬁxed parafﬁn blocks, routine pathological
evaluation, IHC for estrogen receptor (ER), PR, HER2, and Ki-67,
ﬂuorescence in situ hybridization (FISH) for HER2, and tissue
microarray construction were described in our previous report.9 The
present study was approved by the institutional review board of the
National Cancer Center, Tokyo, Japan.
Evaluation of IHC
The methods for evaluation of IHC have been shown in our
previous report.9 Brieﬂy, ER was judged as positive when the Allred
score was 3 and as negative when the score was 211 and PR was
evaluated with 3 cutoff levels of 10%, 20%, and 30%. HER2 was
judged as positive when the IHC score was 3þ or when it was 2þOne patient received CMF and UFT.
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Table 2 Correlation Between Ki-67 LI and PR Expression
Ki-67 LI
Luminal/HER2L Breast Cancer (n [ 368), n (%)
PR 10% Cutoff PR 20% Cutoff PR 30% Cutoff
PRL P PRL P PRL P
10% Cutoff
High (10%; n ¼ 221) 44 (20) .23 76 (35) .11 88 (40) .24
Low (<10%; n ¼ 147) 22 (15) 39 (27) 50 (34)
14% Cutoff
High (14%; n ¼ 163) 37 (23) .03 59 (36) .07 69 (42) .10
Low (<14%; n ¼ 205) 29 (14) 56 (27) 69 (34)
20% Cutoff
High (20%; n ¼ 87) 26 (30) <.001 41 (47) <.001 44 (51) .003
Low (<20%; n ¼ 281) 40 (14) 74 (26) 94 (33)
Total 66 (18) 115 (31) 138 (37)
Abbreviations: LI ¼ labeling index; PR ¼ progesterone receptor.
Makiko Ono et aland the HER2/CEP17 (centromere enumeration probe 17) ratio
was 2.0 in FISH analysis.12 For Ki-67 LI, we selected 2 to 3 areas
per tissue core including hot spots of Ki-67þ cells, and took mul-
tiple photomicrographs of different ﬁelds.13 The photomicrographs
were printed, and the proportion of Ki-67þ cancer cells with
moderate to strong immunoreaction per 1000 cancer cells was
calculated independently by 2 observers (M.O. and H.T.), with the
average value adopted as Ki-67 LI of each case. LA-like and LB-like
subtypes were deﬁned as Ki-67 LI <14% and 14%, respectively.
We evaluated the prognostic signiﬁcances of Ki-67 LI on the basis
of 3 cutoff values, 10%, 14%, and 20%, and of PR expression on
the basis of the cutoff values, 10%, 20%, and 30%.
Statistical Analyses
Statistical analyses were performed using IBM SPSS (SPSS Inc,
Chicago, IL). Correlation analyses were performed using the c2 test
for categorical variables. The interval from the date of initial surgery
to disease recurrence was deﬁned as disease-free survival (DFS), and
the interval from the date of surgery to death from breast cancer or
the last follow-up examination was deﬁned as breast cancer-speciﬁc
survival (BCSS). Death from another disease was regarded as
censored. DFS and BCSS curves were drawn using the
KaplaneMeier method and compared using the log rank test. Cox
univariate and multivariate regression analyses were performed to
evaluate prognostic signiﬁcance of each parameter in patients with
luminal-subtype breast cancers. In all analyses, differences were
considered signiﬁcant at P < .05.
Results
Correlation Between Ki-67 LI and PR Expression
Of 369 tumors, we excluded 1 case because of insufﬁcient ma-
terial for evaluation of PR expression. The details of the 368
luminal/HER2 breast cancer cases are shown in Table 1. There
were 187 patients (51%) who had received adjuvant hormonal
therapy with tamoxifen and 153 (41%) who had received adjuvant
chemotherapy. The median duration of follow-up for all 368 pa-
tients was 118 (range, 0.6-160) months. Overall, 38 recurrences and
14 deaths from breast cancer occurred.The correlation between the Ki-67 LI and PR expression is
shown in Table 2. Although the Ki-67 LI was 10% in 221
(60%), 14% in 163 (44%), and 20% in 87 (24%) of the
tumors, PR expression was <10% in 66 (18%), <20% in 115
(31%), and <30% in 138 (37%). With every cutoff level of Ki-
67 LI, there were substantial PR breast cancers in patients with
low Ki-67 LI breast cancer. For example, 22 (15%) patients with
Ki-67 LI <10% had PR tumors when the cutoff level of PR was
10%, whereas 39 (27%) patients with Ki-67 LI <10% had PR
tumors when the cutoff level of PR expression was 20%. As ex-
pected, the percentage of PR tumors in high and low Ki-67 LI
breast cancers increased as the cutoff level for PR expression went
higher. Simultaneously, the higher the cutoff level of Ki-67 LI,
the more low Ki-67 LI breast cancers were negative for PR.
Accordingly, in case of the 20% Ki-67 LI cutoff level, PR
expression with any cutoff level and Ki-67 LI were inversely
associated (PR 10%, P < .001; PR 20%, P < .001; PR 30%,
P ¼ .003), indicating that 14% to 34% of low Ki-67 LI breast
cancers were negative for PR.
When Ki-67 LI was divided into 6 groups with <5, 5 to 10,
10 to 14, 14 to 20, 20 to 30, and >30%, as shown in Figure 1,
in breast cancers with high Ki-67 LI the percentage of PR-negative
breast cancers increased, showing that Ki-67 LI and PR expression
had a signiﬁcant inverse correlation. Interestingly, when Ki-67
LI was 20%, the number of PR breast cancers greatly
increased. The percentages of PR breast cancers with <20%
Ki-67 LI and 20% Ki-67 LI were 26% and 49%, respectively
(P < .001).
Ki-67 LI and PR Expression as a Prognostic Marker for
Luminal-Like Subtypes
To investigate the prognostic signiﬁcance of PR expression, we
examined the survival analyses for patients stratiﬁed according to 3
subtypes (ie, LA-like/PRþ [LA/PRþ], LA-like/PR [LA/PR], and
LB-like subtypes). When the cutoff value of PR expression was set at
10% or 30%, there was no signiﬁcant difference in DFS between
LA/PRþ and LA/PR breast cancers. However, as shown in
Figure 2A, with a PR expression cutoff level of 20%, DFS wasClinical Breast Cancer Month 2016 - 3
Figure 1 Correlation Between Ki-67 Labeling Index (LI) and
Progesterone Receptor (PgR) Negativity (<20%). Error
Bar Is Presented as SD
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4 - Clisigniﬁcantly different among 3 groups, and 12-year DFS was
94.8%, 81.6%, and 79.7% in LA/PRþ, LA/PR, and LB-like
groups, respectively (P ¼ .03). Strikingly, DFS for patients with
LA/PRþ subtype was quite better than those of the other groups. Of
note, the DFS curve for patients with the LA/PR subtype was close
to that for the LB-like subtype, indicating that the LA/PR subtype
has more aggressive characteristics similar to the LB-like subtype
compared with the LA/PRþ subtype.
Interestingly, recurrence of the LA/PR subtype predominantly
occurred later, and differences in DFS curves between the patient
groups with the LA/PRþ subtype and the LA/PR subtype
emerged 5 years after curative surgery. With regard to BCSS
curves, there was a signiﬁcant difference among patients with
LA/PRþ, LA/PR, and LB-like subtypes, and the 12-year BCSS
rates were 98.4%, 97.5%, and 91.9% in these 3 groups, respectively
(P ¼ .04). Unlike DFS, the BCSS for patients with the LA/PR
subtype was better than that for the LB-like subtype and close to
that for the LA/PRþ subtype.Figure 2 Survival Curves for 368 Patients Stratiﬁed According to Lum
Luminal B Subtypes. (A) Disease-Free Survival (DFS); (B)
nical Breast Cancer Month 2016Cox Univariate and Multivariate Analyses of DFS
In Cox univariate analysis of DFS for patients with the LA-like
subtype, it was shown that large tumor size was a signiﬁcant indica-
tor of worse clinical outcome (hazard ratio, 3.36; 95% conﬁdence
interval [CI], 1.18-9.58; P ¼ .02). Although the signiﬁcance was
marginal, negative PR expression with a cutoff level of 20% also
tended to be correlated with worse clinical outcomes (hazard ratio,
2.81; 95% CI, 0.98-8.00; P¼ .05; Table 3). Likewise, a multivariate
analysis including pT factor and PR showed that both of these factors
remained signiﬁcant or marginally signiﬁcant prognostic factors (tu-
mor size, hazard ratio, 3.36, 95%CI, 1.18-9.59, P¼ .02; PR, hazard
ratio, 2.83, 95% CI, 0.99-8.07, P ¼ .05; Table 4).
In univariate analysis of BCSS for patients with the LA-like
subtype, no factor had any prognostic signiﬁcance (Table 5). This
might be because a few number of events occurred in BCSS.
However, in univariate analysis of DFS for patients with the LB-like
subtype, unlike the LA-like subtype, there was no signiﬁcant
prognostic factor (data not shown), indicating that clinical outcome
in patients with LB-like subtype is inﬂuenced by Ki-67 LI but not
PR expression.
Discussion
For decades, the predictive and prognostic signiﬁcance of PR
expression in breast cancer have been debated, and so far there have
been equivocal data about the role of PR expression in HRþ breast
cancer.10,14 In the present study we showed that PR expression was
a marginally signiﬁcant independent prognostic factor in the LA-like
subtype and that differences in prognosis between LA/PRþ and
LA/PR became evident 5 years after surgery.
A recent meta-analysis has shown a similar reduction in the risk
of recurrence in ERþ/PRþ and ERþ/PR early breast cancers
treated with adjuvant tamoxifen.10 Simultaneously, PR expression
had no inﬂuence on the efﬁcacy of an aromatase inhibitor over
tamoxifen in ERþ early breast cancer patients,15,16 whereas baseline
risk of recurrence is higher in the PR subgroup than the PRþ
subgroup in ERþ breast cancer patients.10 These ﬁndings revealed
that PR expression is a prognostic but not a predictive factor.inal A (LA) Progesterone Receptor (PgR)-Positive, LA/PgRL, and
Breast Cancer-Speciﬁc Survival (BCSS)
Table 3 Cox Univariate Model Analyses for Breast Cancer
Recurrence in 205 Patients With Luminal A (Ki-67
LI <14%) Cancers
Factor Hazard Ratio 95% CI P
Age (£50 vs. >50), Years 0.77 0.26-2.30 .64
Menopause (Pre- vs. Post-) 1.41 0.49-4.02 .52
Pathological T (pT2 or pT3 vs.
pT1)
3.36 1.18-9.58 .02
Grade (3 vs. 1, 2) 2.46 0.69-8.83 .17
Nuclear Grade (3 vs. 1, 2) 2.55 0.80-8.12 .11
Histology (IDC vs. Others) 1.78 0.40-7.97 .45
PR <10% vs. ‡10% 1.15 0.25-4.98 .89
PR <20% vs. ‡20% 2.81 0.98-8.00 .05
PR <30% vs. ‡30% 2.05 0.72-5.84 .18
The P values which are signiﬁcant or almost signiﬁcant are shown in bold.
Abbreviations: IDC ¼ invasive ductal carcinoma; LI ¼ labeling index; PR ¼ progesterone
receptor.
Table 5 Cox Univariate Model Analyses for Breast Cancer-
Speciﬁc Survival in 205 Patients With Luminal A
(Ki-67 LI <14%) Cancers
Factor Hazard Ratio 95% CI P
Age (£50 vs. 50), Years 0.67 0.06-7.44 .75
Menopause (Pre- vs. Post-) 2.72 0.25-30.1 .41
Pathological T (pT2 or pT3 vs.
pT1)
6.48 0.59-71.5 .13
Grade (3 vs. 1, 2) 4.32 0.39-47.7 .23
Nuclear Grade (3 vs. 1, 2) 3.07 0.28-33.8 .36
Histology (IDC vs. Others) 30.45 0.001-2814 .59
PR <10% vs. ‡10% 0.04 0.001-8227 .66
PR <20% vs. ‡20% 1.32 0.12-14.52 .82
PR <30% vs. ‡30% 0.96 0.09-10.60 .97
Abbreviations: IDC ¼ invasive ductal carcinoma; LI ¼ labeling index; PR ¼ progesterone
receptor.
Makiko Ono et alThere have been several molecular mechanisms with the loss of
PR expression in breast cancer reported so far, in which PR is found
to be the end product of estrogen action, and the absence of PR
expression means nonfunctional ER.17 In addition, recent reports
have shown that aberrant growth factor signaling resulted in
reduction of PR expression.18 Indeed, in our cohort including
luminal/HER2þ subtype, luminal/HER2þ breast cancers are more
likely to be negative for PR expression compared with luminal/
HER2 breast cancers (data not shown). All these suggested
mechanisms of the loss of PR expression could be associated with
highly malignant characteristics leading to poor clinical outcomes.
Interestingly, the present study has shown that PR expression
affects late recurrence in the LA-like subtype. Therefore, BCSS for
LA/PR was as good as that for the LA/PRþ subtype over 10 years
after surgery. It is assumed that differences in BCSS between LA/
PRþ and LA/PR would emerge later, even 20 years after surgery.
Because the extended use of hormonal therapy beyond 5 years could
prevent late recurrences,19,20 it is important to clarify the risk factors
of late recurrence in patient selection for its extended use. Previous
studies have reported that proliferation markers and Grade were
important prognostic factors for early recurrence within 5 years after
diagnosis in HRþ breast cancer, but these studies failed to predict
later recurrences.21 Simultaneously, several molecular tests that give
weight to proliferation and cell cycle progression such as Oncotype
DX (Genomic Health, Redwood City, CA) and Mammaprint
(Agendia, Amsterdam) could not signiﬁcantly predict late re-
currences.22,23 These ﬁndings suggest that the molecular mecha-
nism might be different between early and late recurrence. Indeed,Table 4 Cox Multivariate Model Analyses for Breast Cancer
Recurrence in 205 Patients With Luminal A (Ki-67
LI <14%) Cancers
Factor Hazard Ratio 95% CI P
Pathological T (pT2 or pT3
vs. pT1)
3.36 1.18-9.59 .02
PR <20% vs. ‡20% 2.83 0.99-8.07 .05
Abbreviation: LI ¼ labeling index; PR ¼ progesterone receptor.gene signatures related to recurrence risk have been shown to differ
between early and late recurrence.24,25
To date, there have been no reports showing PR expression as a
prognostic marker for late recurrence. However, in a gene expres-
sion analysis, HR signaling was shown to be a risk factor of late
recurrence. The EndoPredict, a gene signature that combines
proliferation-related genes and ER signaling genes, has been re-
ported to predict early and late recurrences.24 Interestingly, the risk
of late recurrences was signiﬁcantly higher in breast cancers with the
higher risk score estimated from expression of 5 ER signaling genes,
RBBP8 (retinoblastoma-binding protein 8), IL6ST (interleukin 6
signal transducer), AZGP1 (alpha-2-glycoprotein 1, zinc-binding),
MGP (matrix Gla protein), and STC2 (stanniocalcin 2), than in
those with the lower risk score.24 Some of these 5 genes are shown
to be regulated by progesterone. Therefore, a low expression level of
PR is implied to be associated with risk of late recurrence.26,27
Similarly with EndoPredict, Breast Cancer Index (BCI) and
PAM50 are able to predict late recurrences as well as early re-
currences in HRþ breast cancer.22,25,28-30 BCI consists of the
Molecular Grade Index (MGI), which depends on proliferation-
related genes, and HOXB13 (homeobox B13):IL17BR (interleukin
17 receptor B) ratio (H/I). MGI is associated with early but not late
recurrence, whereas H/I has a greater prognostic power in late re-
currences than in early recurrences.25
In a study that showed the prognostic signiﬁcance of H/I, PR
expression was not associated with late recurrence risk.31 How-
ever, in that study, the cutoff level of PR expression was much
lower than 20%. In the present study, a PR cutoff level of 10%
did not show a signiﬁcant difference in prognosis in LA-like
breast cancers. In these points, the results of the present study
are consistent with those of previous studies that showed the
importance of a 20% cutoff level for PR in IHC according to the
data of PAM50.6,28,29
We also showed tumor size as an important prognostic factor.
Although nowadays we give weight to breast cancer biology with
subtypes in risk estimation, tumor burden such as tumor size and
nodal status remain important prognostic factors.32 It has been re-
ported that tumor size and nodal status were independent prog-
nostic factors for late recurrence in patients with ERþ breast cancerClinical Breast Cancer Month 2016 - 5
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6 - Clitreated with tamoxifen.21 PAM50 is calculated not only on the basis
of breast cancer subtype but also tumor burden with tumor size.30
These facts might have partly caused the data that PAM50 was a
better prognostic marker than Oncotype DX and IHC4 (the
immunohistochemical 4) in HRþ breast cancers.
Conclusion
We showed that PR expression and tumor size were signiﬁcant or
marginally signiﬁcant independent prognostic factors in the LA-like
subtype and that differences in prognosis between LA/PRþ and
LA/PR became evident 5 years after surgery, resulting in better
prognosis in LA/PR than in the LB-like subtype. In LA-like breast
cancer, stratiﬁcation of prognosis according to PR expression and
tumor size is important.
Clinical Practice Points
 The node-negative invasive breast cancer of the LA-like subtype
is deﬁned as HR-positive, HER2-negative, and Ki-67-low sub-
group and is correlated with good prognosis.
 Nonetheless, a minority of patients with these characteristics
suffer from relapse of and death from LA-like breast cancer.
 In the present study, we examined 205 consecutive patients who
received surgical therapy to node-negative LA-like primary
invasive breast cancer, and 149 (73%) and 56 cases (27%) of
these 205 were PRþ (20% or more cells) and PR (< 20% of
cells), respectively.
 In this LA-like group, in addition to pathological tumor size,
PR negativity was a signiﬁcant indicator of a lower DFS rate:
12-year DFS rates were 94.8% in the LA-like group with
positive PR and 81.6% in the LA-like group with negative PR
status.
 Therefore, the status of PR in node-negative LA-like invasive
carcinoma could be useful in the consideration of adjuvant
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